Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) and EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT), are influenced by contrast since they are both players in the Biotechnology. These factors are particularly influence the profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation of the two firms.
Earnings and Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Enanta Pharmaceuticals Inc.||89||6.26||N/A||3.71||20.20|
|EyePoint Pharmaceuticals Inc.||2||10.92||N/A||-1.37||0.00|
In table 1 we can see Enanta Pharmaceuticals Inc. and EyePoint Pharmaceuticals Inc.’s top-line revenue, earnings per share (EPS) and valuation.
Table 2 represents Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) and EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT)’s return on assets, net margins and return on equity.
|Net Margins||Return on Equity||Return on Assets|
|Enanta Pharmaceuticals Inc.||0.00%||19.3%||18.2%|
|EyePoint Pharmaceuticals Inc.||0.00%||-336.6%||-122.8%|
Risk & Volatility
A 0.97 beta indicates that Enanta Pharmaceuticals Inc. is 3.00% less volatile compared to S&P 500. EyePoint Pharmaceuticals Inc. has a 1.75 beta and it is 75.00% more volatile than S&P 500.
Enanta Pharmaceuticals Inc.’s Current Ratio and Quick Ratio are 20.7 and 20.7 respectively. The Current Ratio and Quick Ratio of its competitor EyePoint Pharmaceuticals Inc. are 2 and 1.9 respectively. Enanta Pharmaceuticals Inc. therefore has a better chance of paying off short and long-term obligations compared to EyePoint Pharmaceuticals Inc.
Institutional and Insider Ownership
Institutional investors owned 91% of Enanta Pharmaceuticals Inc. shares and 62% of EyePoint Pharmaceuticals Inc. shares. Insiders owned 5.5% of Enanta Pharmaceuticals Inc. shares. Competitively, 0.8% are EyePoint Pharmaceuticals Inc.’s share owned by insiders.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Enanta Pharmaceuticals Inc.||-8.31%||-12.8%||-12.18%||-5.06%||-22.96%||5.92%|
|EyePoint Pharmaceuticals Inc.||-4.79%||-18.71%||-16.77%||-34.43%||-38.5%||-26.46%|
For the past year Enanta Pharmaceuticals Inc. had bullish trend while EyePoint Pharmaceuticals Inc. had bearish trend.
Enanta Pharmaceuticals Inc. beats EyePoint Pharmaceuticals Inc. on 7 of the 8 factors.
Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The companyÂ’s research and development focuses on four disease targets: Hepatitis C virus (HCV), Hepatitis B virus (HBV), Non-alcoholic Steatohepatitis (NASH), and Respiratory Syncytial Virus (RSV). Its lead product is paritaprevir, a protease inhibitor designed for use against HCV. The company also develops HCV protease inhibitor in phase III development with AbbVie, as well as a HCV program using a different class of molecules known as cyclophilin inhibitors. In addition, it has a program in non-alcoholic steatohepatitis; and discovers programs in other areas of viral infection and liver disease. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with AbbVie to develop and commercialize HCV NS3 and NS3/4A protease inhibitors. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.
EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company, engages in developing and commercializing ophthalmic products in indications with high unmet medical need to help improve the lives of patients with eye disorders. The company has developed three FDA-approved sustained-release treatments in ophthalmology, including DEXYCU (dexamethasone intraocular suspension), which is administered as a single intraocular dose at the end of ocular surgery for postoperative inflammation; ILUVIEN (fluocinolone acetonide intravitreal implant), a micro-insert for diabetic macular edema; and Retisert (fluocinolone acetonide intravitreal implant) for posterior uveitis. Its lead product candidate is Durasert, (fluocinolone acetonide intravitreal implant), a micro-insert for the treatment of non-infectious uveitis affecting the posterior segment of the eye. In addition, the company’s pre-clinical development program focuses on using its core Durasert platform technology to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. It has license agreements with Bausch and Lomb for Retisert product; a license agreement with Alimera for ocular applications of the ILUVIEN device; and a collaboration agreement with Pfizer for the Durasert device delivering latanoprost. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Watertown, Massachusetts.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.